<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241097</url>
  </required_header>
  <id_info>
    <org_study_id>sxse</org_study_id>
    <nct_id>NCT01241097</nct_id>
  </id_info>
  <brief_title>Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe</brief_title>
  <official_title>Comparison of the Effect on Endothelial Function of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Escola Bahiana de Medicina e Saude Publica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Bahia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To test the hypothesis that therapy with high dose statin provides endothelial superior
           benefit to the same cholesterol lowering with low-dose statin combined with ezetimibe.

        -  To test the hypothesis that therapy with high dose statin provides anti-inflammatory
           effect than the same reduction of cholesterol with low dose of statin plus ezetimibe
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled study. Inclusion Criteria: Obese women with body
      mass index (BMI)&gt; 25 kg / m², aged 18 years and LDL-C&gt; 100 mg / dl For treatment with
      simvastatin 80 mg, the participant will receive two identical vials, each containing a
      simvastatin 40 mg. For treatment with the combination simvastatin 10 mg and ezetimibe 10 mg,
      the participant will receive two identical bottles, one bottle with simvastatin 10 mg, and
      another bottle with ezetimibe 10mg. In the control group, each participant will receive two
      identical bottles, each bottle containing inert tablets. Each group with 20 participants.

      Dependent Variable (Final Primary Outcome): Percentage change vasodilation of brachial artery
      flow-mediated, after treatment for eight weeks.

      Covariates: clinical, biochemical markers and ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change vasodilation of brachial artery flow-mediated, after eight weeks of treatment.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical markers</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>high-dose simvastatin, combined, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin, combined with simvastatin ezetimibe, placebo</intervention_name>
    <description>simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo</description>
    <arm_group_label>high-dose simvastatin, combined, placebo</arm_group_label>
    <other_name>zocor, vytorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with body mass index (BMI)&gt; 25 kg / m²

          -  Aged &gt; 18 years

          -  LDL-C&gt; 100 mg / dl

        Exclusion Criteria:

          -  Previous use of statins, fibrates or ezetimibe

          -  Triglycerides&gt; 400 mg / dl

          -  Serum creatinine greater than 2.0 md / dl

          -  Elevated liver enzymes, more than one and half times the upper limit of normal

          -  Creatine kinase (CK) levels more than three times the upper limit of normal

          -  Pregnant

          -  Breast-feeding

          -  Heart failure

          -  Psychiatric disorders

          -  Hormone replacement therapy.

          -  The occurrence of recent onset within the last four weeks of treatment with
             beta-blockers, converting enzyme inhibitor or calcium channel blocker, the
             intervention should be undertaken after a period of at least four weeks of continuous
             use.

          -  Acute inflammatory processes in the last month, assessed by clinical history and
             physical examination (ear, throat, skin lesions or other inflammatory manifestations)
             as well as reports of chronic diseases such as collagen, or the occurrence of active
             tuberculosis in the last three months will be excluded from work.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maristela M Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Escola Bahiana de Medicina e Saúde Pública</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maristela M Garcia, MD</last_name>
    <phone>55-71-99739981</phone>
    <email>marismacardiol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Claudio L Correia, Phd</last_name>
    <phone>55-71-99711032</phone>
    <email>lccorreia@terra.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Escola Bahiana de Medicina e Saúde Púiblica</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilia G Rodrigues, MD</last_name>
      <phone>55-71-3359485</phone>
      <email>mgaleffi@cardiol.br</email>
    </contact>
    <contact_backup>
      <last_name>Paulo Roberto P Lima, student</last_name>
      <phone>55-71-99184765</phone>
      <email>prpassoslima@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carolina Garcez, student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>November 15, 2010</last_update_submitted>
  <last_update_submitted_qc>November 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Luis Claudio Lemos Correia, Phd</name_title>
    <organization>Escola Bahiana de Medicina e Saude Publica</organization>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>statins</keyword>
  <keyword>ezetimibe</keyword>
  <keyword>pleiotropism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

